The EUS appearance of lymph nodes in patients undergoing evaluation for malignancy was studied. Methods: In 378 patients EUS characteristics were assessed: size of tumor, largest lymph node size, number of lymph nodes, distance of lymph nodes from the tumor, and on a 5-point visual analogue scale (1 = least malignant to 5 = most malignant), roundness, homogeneity, and echogenicity. A morphology score (sum of roundness, homogeneity, and echogenicity) was calculated. 
EUS is a sensitive means for detecting lymph nodes in proximity to the GI tract. 1 In patients with malignancies enlarged lymph nodes may indicate nodal metastasis. 2 Patients with nodal metastasis have, in general, a poorer prognosis. Identifying these patients preoperatively may improve outcome by selecting patients for neoadjuvant chemoradiotherapy protocols or sparing them from therapies that are not beneficial.
Whether EUS can discriminate benign from malignant adenopathy is controversial. Lymph nodes may enlarge when they are malignant or as part of an inflammatory reaction. 3, 4 Catalano et al., 1 studying patients with esophageal cancer, reported that lymph nodes greater than 1 cm that are round, hypoechoic (dark), homogeneous, and well-demarcated predicted malignancy with accuracy of up to 100%. 1 Most other studies have reported the accuracy of EUS to be no better than 70% to 80% for lymph node histology. [5] [6] [7] [8] [9] [10] [11] EUS-guided fine needle aspiration (EUS-FNA) has been advocated when lymph node histology would alter treatment. 12, 13 However, not all lymph nodes are amenable to EUS-FNA because of intervening tumor or other structure, and EUS-FNA is not universally available.
An accurate means for discriminating benign from malignant adenopathy without aspiration would be desirable. Prior studies attempting to identify relevant findings have had several shortcomings. Terms such as "round," "dark," or "homogeneous" are vague. They have been used as dichotomous variables ("round" vs. "not round," "dark" vs. "bright") when in fact there is a continuous range. 1, 12 In addition, whether criteria developed for one clinical situation (e.g., esophageal cancer) can be used in another (e.g., pancreatic cancer) is unknown. 11 It may be possible to use combinations of criteria to identify patient subgroups with a high likelihood of having or not having malignant adenopathy. 1 This study was performed to systematically examine different lymph node characteristics. In addition to size, the number of lymph nodes identified and their proximity to the primary tumor were assessed. The nodal characteristics of shape, echogenicity, and homogeneity were studied by using visual analogue scales and a combined calculated morphology score. Subgroup analysis by tumor type or lymph node location was also performed.
PATIENTS AND METHODS
Consecutive patients undergoing clinically indicated EUS evaluation between July 1, 1996 and December 31, 1999 for known or suspected malignancy were studied. Only patients in whom lymph nodes were identified were included. EUS was performed at 7.5 and 12 MHz by a single experienced endosonographer with a radial sector scanning system (GFUM20, Olympus America, Inc., Melville, N.Y.). The following EUS data were collected at the time of the procedure and assessed by a single observer: TNM stage, tumor size, largest lymph node size (long axis), number of lymph nodes identified, and proximity of the closest lymph node to the tumor. If the tumor and lymph node were not visualized in the same axial plane, lymph node distance was estimated by the markings on the exterior of the endoscope. The hypothesis of the study was that lymph nodes that are round, dark, and homogeneous will more likely be malignant. For each patient, the most malignant-appearing lymph node was assessed with a 5-point visual-analogue scale (1 = least malignant to 5 = most malignant) for roundness, echogenicity, and homogeneity (Fig. 1) . A morphology score was calculated by adding the scores for roundness, echogenicity, and homogeneity (minimum 3 to maximum 15). Celiac lymph nodes were assessed separately. Informed consent was obtained before each procedure. Because this study was an analysis of data already being collected at the time of a clinically indicated procedure, specific institutional review board approval was not required. The study was carried out in accord with the Helsinki declaration.
EUS findings were compared with subsequent histopathology by EUS-FNA or surgery. EUS-FNA was performed with a linear array (FG36UX with Hitachi processor, Pentax Precision Instruments, Orangeburg, N.J.). The Echotip needle (Wilson-Cook, Winston-Salem, N.C.) or GIP needle (Mediglobe, Grassau, Germany) were used. A cytotechnologist but not a pathologist was present at each procedure to assess adequacy of the specimen, and a minimum of 3 passes were performed. The Pentax instrument was not used to determine lymph node characteristics. Surgical pathology was determined retrospectively by record review. Patients were considered to have malignant adenopathy if any lymph node was positive by FNA cytology or surgical pathology. Benign adenopathy was diagnosed if a surgical or FNA cytology was performed and was negative for malignancy.
Associations between lymph node histopathology (presence or absence of malignant cells) and the EUS data were assessed for statistical significance with the JMP module of SAS software (SAS Institute, Cary, N.C.). Univariate analysis with Student's t test or the Pearson chi-square test for parametric and non-parametric data was initially performed to identify variables for multivariate analysis. Multiple stepwise regression analysis was then performed on those variables identified by univariate analysis to have a p value of at least 0.2. The type of lymph node histology (EUS-FNA or surgery) was also included in the model to control for possible confounders caused by assessment type. This analysis was done for the entire group and for the subset who did not receive preoperative chemotherapy or radiotherapy. Multivariate analysis was then done on the following subgroups: patients with esophageal cancer or pancreaticobiliary malignancies, those with mediastinal lymph nodes (excluding esophageal cancer), and those with lymph nodes in the region of the celiac artery. Multivariate p values < 0.05 were considered significant.
RESULTS
Three hundred seventy-three patients with lymph nodes identified at EUS were studied (Table 1) . Of these, 238 (64%) had lymph node biopsies at surgery (n = 109), EUS-FNA (n = 144), or both (n = 15) and formed the cohort for the analysis. The prevalence of malignant adenopathy was 51%. The majority of the cohort (63%) had either esophageal or pancreaticobiliary malignancies. Thirty-five patients had mediastinal lymph nodes without esophageal cancer or an extra-thoracic primary tumor; an additional 14 had pancreatic masses and 4 had other extra-thoracic primaries and underwent EUS-FNA of enlarged mediastinal lymph nodes.
By multivariate analysis, largest lymph node size, distance from the primary tumor, and the morphology score were independently associated with lymph node histopathology ( Table 2 ). Tumor size, T-stage, number of lymph nodes, and the type of lymph node histopathology (EUS-FNA or surgery) were not significant. The individual characteristics of roundness, echogenicity, and homogeneity were significant by univariate analysis. By multivariate analysis, they were not independent of each other. Excluding patients who had received chemotherapy or radiotherapy (data not shown) did not change the significance of these associations. When the multivariate model was back applied on the data it was 64% accurate in predicting histology in the entire cohort and 74% accurate in the subgroup that did not receive chemoradiotherapy.
The morphology score, which is the sum of the scores for roundness, echogenicity, and homogeneity and can range from 3 to 15, correlated with lymph node histopathology (Table 3) . For patients with a morphology score of 6 or less (12% of the cohort), only 7% had malignant lymph nodes. For those with a score of at least 13 (34% of the cohort), 63% had malignant lymph nodes. Among those with a score of 15 (14% of the cohort), 79% had malignant lymph nodes. Chemoradiotherapy is known to decrease the accuracy of EUS assessment. 14, 15 Excluding the 38 patients who had received chemotherapy or radiotherapy increased the positive predictive value of a high morphology score to 73% for a score of 13 to 15 and to 83% for a score of 15.
Subgroup analysis by primary site is shown in Table 4 with p values by multivariate analysis. Lymph node size was significant for patients with esophageal cancer or mediastinal lymph nodes, but not for pancreaticobiliary cancers or celiac lymph nodes. Distance from the primary tumor was significant for pancreaticobiliary tumors but not esophageal tumors. Distance from tumor is not assessed for the mediastinal and celiac nodal sites because the primary tumor may or may not be evident. The morphology score remained significant for all sites.
This study used either surgical pathology or EUS-FNA to provide a tissue diagnosis. Patients with surgical biopsies as compared with patients who had undergone EUS-FNA had lymph nodes that were smaller (1.1 ± 0.1 vs. 1.9 ± 0.1, p < 0.001), but closer to the primary tumor (1.2 ± 0.4 vs. 3.5 ± 0.4, p < 0.0001) and with a higher morphology score (11.6 ± 0.3 vs. 10.4 ± 0.3, p < 0.01). To control for possible bias, the type of histologic assessment was included in the multivariate model. Lymph node size, distance, and morphology remained statistically significant, but method of histopathologic assessment was not (p = 0.6).
DISCUSSION
This study examined correlations between EUS findings and lymph node histology. Only patients with lymph nodes identified by EUS were included. Therefore, the sensitivity of EUS for the detection of lymph nodes cannot be assessed. What can be assessed are associations between the EUS findings and histology, and the predictive value of these findings. In general, patients with malignant adenopathy (Fig. 2) have lymph nodes that are larger, closer to the primary tumor, rounder, darker, and more homogeneous than patients without malignant adenopathy (Fig. 3) . The number of lymph nodes identified and the size of the primary tumor were not significant.
These criteria can be used to identify patients with a high likelihood of having benign or malignant lymph nodes (Table 5 ). The combination of identifying at least 1 lymph node greater than 1 cm in size, at least 1 lymph node within 1 cm of the tumor, and a high morphology score was 76% to 100% predictive of the presence of malignant adenopathy. A morphology score of 14 or greater in combination with large and closely placed lymph nodes had a positive predictive value (PPV) of 81% and was present in 13% of the cohort. For a morphology score of 6 or less, the negative predictive value (NPV) was 93% (prevalence 12%); adding size and distance considerations did not improve the NPV. Thus with these criteria, in approximately one quarter of patients it is possible to predict lymph nodal histology with 80% to 93% accuracy.
This study clearly demonstrates that the morphologic features of roundness, echogenicity, and homogeneity on EUS are associated with histology. Morphology was the only factor that was significant for all sites (Table 4) . Catalano et al. 1 studied 100 patients with esophageal cancer and also found that the morphologic features of shape, border sharpness, and echopattern were significantly associated with malignancy. This study expands this observation to show that morphology is important for other anatomic sites and for pancreaticobiliary malignancies, and that morphology is independent of other indicators such as size and proximity to the primary tumor. The visual assessment of morphology, even with visual analogue scales to improve standardization, is by its nature subjective. The use of computerized systems to analyze lymph node characteristics may yield different results. Size and proximity of lymph nodes to the primary tumor were also independent predictors of malignancy. This study used long axis rather than short axis to examine size independently from shape. For irregularly shaped lymph nodes it is relatively straightforward to measure the long axis (the largest measurable size), but an identifiable short axis may not be present (Fig. 3) . Using a long:short axis ratio to quantify roundness is similarly problematic. For example, an equilateral triangle would have a long: short axis ratio of 1 (the same as a circle) whereas the visual analogue scale used in this study would more accurately describe this lymph node shape as "irregular" with a score of 1. It is possible that if the analysis was restricted to only round and oval lymph nodes, measuring the short axis would yield different results. In the studies of Catalano et al., 1 Bhutani et al., 12 and Aibe et al., 16 long axis size was measured and was significant in the former two studies but not the latter. Lymph node proximity has not previously been studied and was an independent predictor for malignancy in patients with pancreaticobiliary malignancies.
Differences according to primary site may indicate a need for site-specific criteria (Table 4) . For esophageal cancer, lymph nodes 1 cm or greater that were within 1 cm of the tumor and that had a morphology score of 14 or greater, had a PPV of 80% and were present in 23% of the cohort (PPV = 87% when prior chemoradiotherapy was excluded; prevalence = 26%). For pancreaticobiliary malignancies in which size was not a significant factor, lymph nodes within 2 cm of the tumor and with a morphology score of 12 or greater had a PPV of 90% but were present in only 9%. For patients without esophageal cancer but with mediastinal lymph nodes, distance from the primary tumor usually cannot be assessed. Patients with mediastinal lymph nodes of 1 cm or greater and a mor- phology score of 14 or greater had a PPV of 67% (prevalence = 11%). This decreased PPV for mediastinal lymph nodes has been noted by others and is probably because of the high prevalence of reactive adenopathy in the mediastinum. 11, 17 For celiac lymph nodes where size was not significant and distance from the primary tumor is not usually a consideration, a morphology score of 12 or greater had a PPV of 75% (prevalence = 34%). This PPV is less than the 91% reported by Catalano et al. 11 The Catalano study was smaller, including only 25 patients with celiac lymph nodes identified, was limited to patients with esophageal cancer, and used EUS-FNA in only 4 patients. In contrast to PPV, a morphology score of 6 or less had NPVs of 86% for celiac lymph nodes, 90% for pancreaticobiliary, and 100% for esophageal and mediastinal lymph nodes. Thus, for determining whether a lymph node is malignant, the primary site must be considered and criteria adjusted somewhat. Treatment with radiotherapy or chemotherapy also must be considered because this decreases the predictive value. Tumor histology has also been suggested as an important consideration, with one study showing better accuracy for differentiated than undifferentiated gastric cancer. 18 Tumor histology was not examined in this study. The major limitation to this type of research is defining an accurate criterion standard. Surgical exploration would appear to be the best standard for comparison, but there are several limitations to relying on surgery. Not all patients ultimately undergo surgery. This is often due to findings of advanced cancer by EUS or CT. This selection bias would result in a higher proportion of patients with false-negative EUS (no malignant lymph nodes identified) being included. It is difficult to standardize surgical technique, particularly for lymph node dissection. Identifying all lymph nodes on the resected specimen is not always easy, and specialized pathologic techniques may increase the yield. 10 EUS-FNA is also an imperfect standard. The advantage of this approach is the ability to directly correlate EUS findings with lymph node histopathology. But EUS-FNA is limited by the fact that not all lymph nodes are accessible to FNA because of small size or location behind an intervening tumor or other structure such as a blood vessel. Thus FNA likely underestimates the prevalence of malignant lymph nodes as compared with surgical staging and may lead to a falsely increased estimate of the NPV.
This study used either surgical pathology or EUS-FNA to provide a tissue diagnosis. It was recognized that the type of histologic assessment (surgical or EUS-FNA) might influence the results. Patients who had undergone surgical biopsies, as compared with those who had undergone EUS-FNA, had lymph nodes that were smaller but closer to the primary tumor with a higher morphology score. These differences are partially because small lymph nodes located close to a primary tumor are less accessible to EUS-FNA. To control for possible bias, the type of tissue assessment was included in the multivariate model. Lymph node size, distance, and morphology remained statistically significant but tissue assessment method was not (p = 0.6).
The way these data should be used depends on the clinical situation. When highly benign-appearing lymph nodes are identified (morphology score ≤6), EUS-FNA may not be worth the effort and expense. In this situation, which carries a negative predictive value of 93%, FNA would add only 4% to 6% to the NPV. When highly suspicious lymph nodes are present (i.e., lymph nodes that are 1 cm or greater), within 1 cm of the tumor and with a morphology score of at [19] [20] [21] and in this situation with a pretest probability of 80%, a patient with a negative FNA would still have up to a 44% chance of having malignant lymph nodes. 22 If the presence of malignant lymph nodes would lead to additional therapy, such as neoadjuvant therapy for patients with esophageal cancer, then EUS criteria alone may be sufficient because FNA cannot rule out malignant adenopathy. If, on the other hand, the presence of malignant adenopathy would exclude a patient from a potentially beneficial treatment, then a tissue diagnosis is necessary. This latter situation is common in pancreatic cancer in which lymph node metastasis indicates an extremely poor prognosis and may contraindicate pancreaticoduodenectomy 23 and when celiac lymph nodes are found in esophageal cancer. 11, 13 The one caveat that should be noted is that because this is a single observer study from one institution, the generalizability of the results needs to be confirmed. It is justifiable to say that in most cases the EUS criteria will be equivocal and EUS-FNA should be performed if the results would alter clinical management. In summary, this study confirms that EUS features are significantly correlated with the presence or absence of malignant adenopathy. In general, patients with malignant adenopathy have lymph nodes that are larger, closer to the primary tumor, rounder, darker (hypoechoic), and more homogeneous compared with patients without malignant lymph nodes. In approximately one quarter of patients, it is possible to predict lymph nodal histopathology with 80% to 90% certainty. In the majority of patients, EUS-FNA is necessary if the results would alter clinical plans.
